In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Promethean Fires Up AC-11 Cosmeceutical Line With Optigenex Deal

This article was originally published in The Rose Sheet

Executive Summary

Promethean Corporation aims to launch nutritional supplements and a topical skin-care system in 2010 under a deal with Optigenex granting it access to the latter's AC-11 compound for DNA repair

You may also be interested in...



Experts Discuss Exotic Actives, Ingredient Sourcing Challenges In Amazonia

In-Cosmetics speakers agreed that sustainable sourcing and environmental protection measures are critical in the Amazon where the rich but increasingly imperiled ecosystem continues to provide skin-care formulators with exotic new ingredients for combating aging.

Experts Discuss Exotic Actives, Ingredient Sourcing Challenges In Amazonia

In-Cosmetics speakers agreed that sustainable sourcing and environmental protection measures are critical in the Amazon where the rich but increasingly imperiled ecosystem continues to provide skin-care formulators with exotic new ingredients for combating aging.

Keep An Eye On Neighboring Industries For Next Big Cosmetic Ingredient

With consumers seeking multi-dimensional sensory experiences from the goods they buy, fragrance and personal-care innovators should be looking to give-and-take with outside industries, according to Amy Marks-McGee, founder of consulting firm Trendincite

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel